Literature DB >> 29437640

The immunoglobulin heavy chain 3' regulatory region superenhancer controls mouse B1 B-cell fate and late VDJ repertoire diversity.

Nour Ghazzaui1, Hussein Issaoui1, Alexis Saintamand1, Christelle Oblet1, Claire Carrion1, Yves Denizot1.   

Abstract

The immunoglobulin heavy chain (IgH) 3' regulatory region (3'RR) superenhancer controls B2 B-cell IgH transcription and cell fate at the mature stage but not early repertoire diversity. B1 B cells represent a small percentage of total B cells differing from B2 B cells by several points such as precursors, development, functions, and regulation. B1 B cells act at the steady state to maintain homeostasis in the organism and during the earliest phases of an immune response, setting them at the interface between innate and acquired immunity. We investigated the role of the 3'RR superenhancer on B1 B-cell fate. Similar to B2 B cells, the 3'RR controls μ transcription and cell fate in B1 B cells. In contrast to B2 B cells, 3'RR deletion affects B1 B-cell late repertoire diversity. Thus, differences exist for B1 and B2 B-cell 3'RR control during B-cell maturation. For the first time, these results highlight the contribution of the 3'RR superenhancer at this interface between innate and acquired immunity.
© 2018 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29437640      PMCID: PMC5812333          DOI: 10.1182/bloodadvances.2017014423

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  35 in total

1.  IMGT(®) tools for the nucleotide analysis of immunoglobulin (IG) and T cell receptor (TR) V-(D)-J repertoires, polymorphisms, and IG mutations: IMGT/V-QUEST and IMGT/HighV-QUEST for NGS.

Authors:  Eltaf Alamyar; Patrice Duroux; Marie-Paule Lefranc; Véronique Giudicelli
Journal:  Methods Mol Biol       Date:  2012

Review 2.  Development of B cells producing natural autoantibodies to thymocytes and senescent erythrocytes.

Authors:  Richard R Hardy; Kyoko Hayakawa
Journal:  Springer Semin Immunopathol       Date:  2004-12-21

3.  Elucidation of IgH 3' region regulatory role during class switch recombination via germline deletion.

Authors:  Alexis Saintamand; Pauline Rouaud; Faten Saad; Géraldine Rios; Michel Cogné; Yves Denizot
Journal:  Nat Commun       Date:  2015-05-11       Impact factor: 14.919

Review 4.  B cells in the aging immune system: time to consider B-1 cells.

Authors:  Nichol E Holodick; Thomas L Rothstein
Journal:  Ann N Y Acad Sci       Date:  2015-07-20       Impact factor: 5.691

5.  Targeting the oncogene B lymphoma deregulator IgH 3' regulatory region does not impede the in vivo inflammatory response in mice.

Authors:  Faten Saad; Alexis Saintamand; Pauline Rouaud; Yves Denizot
Journal:  Oncoscience       Date:  2014-09-19

6.  bcRep: R Package for Comprehensive Analysis of B Cell Receptor Repertoire Data.

Authors:  Julia Bischof; Saleh M Ibrahim
Journal:  PLoS One       Date:  2016-08-23       Impact factor: 3.240

7.  Efficient role of IgH 3' regulatory region deficient B-cells in the development of oil granulomas.

Authors:  Nour Ghazzaui; Alexis Saintamand; Hussein Issaoui; Faten Saad; Yves Denizot
Journal:  Oncotarget       Date:  2016-06-21

8.  Functional anatomy of the immunoglobulin heavy chain 3΄ super-enhancer needs not only core enhancer elements but also their unique DNA context.

Authors:  Sandrine Le Noir; François Boyer; Sandrine Lecardeur; Mylène Brousse; Zeliha Oruc; Jeanne Cook-Moreau; Yves Denizot; Michel Cogné
Journal:  Nucleic Acids Res       Date:  2017-06-02       Impact factor: 16.971

Review 9.  The IgH 3' regulatory region and c-myc-induced B-cell lymphomagenesis.

Authors:  Nour Ghazzaui; Alexis Saintamand; Hussein Issaoui; Christelle Vincent-Fabert; Yves Denizot
Journal:  Oncotarget       Date:  2017-01-24

10.  B-1a, B-1b and B-2 B cells display unique VHDJH repertoires formed at different stages of ontogeny and under different selection pressures.

Authors:  U C Tornberg; D Holmberg
Journal:  EMBO J       Date:  1995-04-18       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.